ClinicalTrials.gg

TargetBeta

MET

MET proto-oncogene, receptor tyrosine kinase · also HGFR, RCCP2, DFNB97 · IPT domain containing

25 programs in company-led studies act on MET, from 18 companies: 9 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
cabozantinibruleExelixisphase 43610 runningKDRChEMBL
CrizotinibrulePfizerphase 4312 runningALK, EML4, MST1R, NPM1, ROS1NCIt
telisotuzumab adizutecanAbbViephase 31818 running–the company's pipeline
zanzalintinibruleExelixisphase 31715 runningAXL, KDRNCIt
amivantamabruleJohnson & Johnsonphase 31613 runningEGFRNCIt
vebreltinibruleBeijing Pearl Biotechnology Limited Liabilityphase 394 running–NCIt
glumetinibruleHaihe Biopharmaphase 384 running–NCIt
bafisontamabruleShanghai EpimAb Biotherapeuticsphase 354 runningEGFRNCIt
HS-20117Hansoh Pharmaceutical Groupphase 333 runningEGFRthe company's pipeline
vilzemetkibSino Biopharmaceuticalphase 382 runningAXLthe company's pipeline
dalmelitinibHansoh Pharmaceutical Groupphase 372 running–a judged reading
SHR-1826Jiangsu HengRui Medicinephase 277 running–the company's pipeline
TQB2922Sino Biopharmaceuticalphase 255 runningEGFRthe company's pipeline
pamvatamigruleBetta Pharmaceuticalsphase 254 runningEGFRNCIt
c-Met Inhibitor ANS014004ruleAvistone Biotechnologyphase 233 running–NCIt
TQB6411Sino Biopharmaceuticalphase 233 runningEGFRthe company's pipeline
Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703ruleChong Kun Dang Pharmaceuticalphase 211 running–NCIt
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 211 runningEGFRNCIt
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruleTavotek Biotherapeuticsphase 122 runningEGFR, VEGFANCIt
HS-20122Hansoh Pharmaceutical Groupphase 122 runningEGFRthe company's pipeline
ABBV-253AbbViephase 111 running–the company's pipeline
Anti-c-Met Antibody-drug Conjugate YL211MediLink Therapeutics (Suzhou)phase 111 running–the company's pipeline
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 111 runningEGFRa judged reading
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 111 runningEGFRNCIt
HLX48Fosun Pharmaphase 111 runningEGFRthe company's pipeline

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.